Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus Clinical Trial

— DARE  

Official title:

Dipyridamole Assessment for Flare Reduction in SLE

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01781611
• Other study ID #: IRB# 12-10
• Status: Terminated
• Phase: N/A
• Start date: February 2013
• Est. completion date: November 2017

Study information

• Verified date: November 2020
• Source: Oklahoma Medical Research Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dipyridamole, a medication extensively used in combination with aspirin for stroke prevention, is a promising new treatment for lupus. Dipyridamole has been shown to inhibit certain lymphocyte populations that are over-reactive in lupus and to delay the emergence of lupus-related pathology in mice with lupus. The investigators are interested in investigating the efficacy of dipyridamole in preventing flares in patients with lupus and its impact on biomarkers of disease activity.

Description:

T cells in systemic lupus erythematosus (SLE) express an abnormal phenotype characterized by increased effector functions and deficient regulatory responses. Dipyridamole, a phosphodiesterase inhibitor extensively used in combination with low dose aspirin in secondary stroke prevention, has been proposed as a specific T cell directed treatment for SLE. Dipyridamole inhibits the calcium/calcineurin/NF-AT pathway in SLE T cells in vitro and abrogates expression of cytokines and costimulatory molecules, eventually also affecting B cell responses. Dipyridamole delays the emergence of lupus related pathology in lupus prone mice, but has not yet been studied in humans with SLE. The investigators aim to investigate the efficacy of dipyridamole in the prevention of flares in SLE patients after withdrawal of background immunosuppressive medications. The investigators will additionally evaluate the safety and tolerability of dipyridamole and its impact on quality of life measures in this population. Furthermore, the effect of dipyridamole on T and B cell biomarkers will be examined.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 18
• Est. completion date: November 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with SLE meeting the 1997 ACR Classification Criteria

• Evidence of positive ANA or anti-dsDNA within one year of screening

• SLEDAI =4 or =1 BILAG A or B at screening, despite standard of care

Exclusion Criteria:

• Leukopenia (WBC <2.000/mm3) or lymphopenia (lymphocytes < 300/mm3)

• AST or ALT >3 times above normal cut off values

• Acute lupus nephritis defined as class II, IV or V nephritis diagnosed within 6 months or prot/creat > 1.5 gm/gm due to active lupus or in process of receiving induction therapy for nephritis

• Active CNS lupus affecting mental status

• Pregnancy or breast feeding

• Current requirement for anticoagulation

• Contraindication to aspirin or dipyridamole, including history of recent or severe GI bleeding, hemoglobin <9 mg/dL, platelet count of <30,000 /mm3 or unstable platelet count

• Any other medical condition, whether or not related to lupus which, in the opinion of the investigator would render the patient inappropriate or too unstable to complete the study protocol

• Inability or unwillingness to understand and/or sign informed consent

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic
• Systemic Lupus Erythematosus

Intervention

Drug:
• extended release dipyridamole 200mg/aspirin 25mg
one tablet twice daily for 24 weeks
• 81mg aspirin
half a tablet twice daily for 24 weeks

Locations

Country	Name	City	State
United States	Oklahoma Medical Research Foundation	Oklahoma City	Oklahoma

Sponsors (1)

Lead Sponsor	Collaborator
Oklahoma Medical Research Foundation

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kyttaris VC, Zhang Z, Kampagianni O, Tsokos GC. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum. 2011 Jul;63(7):2058-66. doi: 10.1002/art.30353. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	British Isles Lupus Assessment Group Index-based Combined Lupus Assessment (BICLA)	This is a landmark measure of percentage of patients who meet response criteria. To meet the BICLA response measure a patient must, compared to baseline, have a decrease in all moderate or severe scores on the British Isles Lupus Assessment Group (BILAG) index by at least one severity grade (Severe disease (BILAG A score) must drop to at least moderate (B or better) and B must drop to at least mild (C or not present). Also, there must be no increase in any other BILAG organ scores, no increase in The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, and no increase in the physician's global assessment (PGA) by more than 10% of the scale. Furthermore, there may no off protocol medication increases. Note on all scales mentioned a higher score signifies greater disease activity. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76.	24 weeks
Secondary	Systemic Lupus Erythematosus Responder Index (SRI) 4	This is a landmark analysis of percentage of patients who meet the following response criteria: Compared to baseline there must be a 4 point decrease in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), no increase in The British Isles Lupus Assessment Group (BILAG) Index score and no more of an increase in Physician's Global Assessment (PGA) than 10% of the scale. As assessed here, there must also be no off protocol increase in medications. All scales signify worsening disease when scores increase. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76.	24 weeks
Secondary	SRI Component Analyses: 4 Point Drop in SLEDAI	This is a landmark analysis of percentage of patients who, compared to baseline, have a 4 point drop in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). A 4 point decrease signifies a clinically significant decrease in disease activity as reported in many studies and as commonly used as a clinical endpoint in trials. SLEDAI could range 0-105 but is rarely greater than 20.	24 weeks